A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Background Obesity is one of the critical public health problems in our society. It leads to various health conditions, such as type 2 diabetes mellitus, cardiovascular disease, hypertension, dyslipidaemia, and non-alcoholic fatty liver disease. With the rising incidence of obesity, there is a growing demand for new therapies which can effectively manage body weight and improve health. Current evidence Currently under development, multi-receptor agonist drugs may offer a promising solution to meet this unmet medical need. Retatrutide is a novel triple receptor agonist peptide that targets the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). This novel drug has the potential to treat metabolic abnormalities associated with obesity as well as diseases resulting from it due to its distinct mechanism of action. The Phase III trial of this pipeline drug for treating type 2 diabetes mellitus, non-alcoholic fatty liver disease, and obesity started on August 28, 2023. The results of a Phase II clinical trial have demonstrated significant weight reduction in overweight and obese adults. Specifically, the trial reported an average weight loss of 17.5% and 24.4% at 24 and 48 weeks, respectively. Conclusions These findings hold promise for the development of effective weight loss interventions in this population group. There is a need for more phase III studies to provide sufficient clinical evidence fo…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, activating multiple receptors may lead to more complex side effects, and in some experiments, dual and triple agonists have indeed shown more severe side effects.165,166”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [165]
In the citing paper
“Retatrutide combines appetite suppression (GLP-1, GIP) with increased energy expenditure via glucagon receptor stimulation. This multifaceted mechanism targets both caloric intake and energy metabolism and enhances insulin secretion, optimizes glucose homeostasis, and effectively regulates appetite [70].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [70]
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 2×
“It also encourages the glucose-induced production of insulin, which replenishes the reserves of insulin in beta cells [11–13].”
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 1×
“…to directly activating brain regions that the molecule can reach, GLP-1 receptors may also affect neuronal activity in other brain regions, such as the lateral parabrachial nucleus, that are involved in the regulation of appetite, food intake, food preference, reward, and meal termination [19–22].”
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 1×
“Because of this complex interaction, the satiating effects of exogenous GLP-1 when given intraperitoneally require an intact vagus nerve but not when given intravenously [17, 18].”
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161 · cited 1×
“GIP is quickly broken down by DPP-4 to create the inactive GIP (3–42) metabolite [25].”
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882 · cited 3×
“The drug’s (0.1 nmol/kg) effect on glucose decrease in wild-type mice during an ipGTT demonstrated this, since it maintained an ED50 similar to the tripeptide’s (0.2 nmol/kg) [33].”
InfluentialGIP and GLP-1, the two incretin hormones: Similarities and differences
Seino, Y., Fukushima, M., & Yabe, D. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00022.x · Cited by 746 · cited 1×
“Modulation of feeding has been associated with GIPR expression in the hypothalamus, namely, in the dorsomedial, paraventricular, and arcuate nuclei—three hypothalamic regions related to energy balance [26, 27].”
Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717
Mechanisms of action of glucagon-like peptide 1 in the pancreas
Doyle, M. E., & Egan, J. M. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.007 · Cited by 680
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541 · cited 1×
“CAMP research evaluated the effectiveness and potency of drugs using low receptor-density clonal cell lines, which provided accurate and little signal pathway amplification [30].”
Research works printed but not linked: 2
- Purnell JQ (2000) Definitions, Classification, and Epidemiology of Obesity. In: Feingold KR, Anawalt B, Blackman MR et al (eds) Endotext [Internet]. MDText.com, Inc., South Dartmouth (MA). https://www.ncbi.nlm.nih.gov/books/NBK279167/
- Chaudharya M, Sharma P (2023) Abdominal obesity in India: analysis of the National Family Health Survey-5 (2019–2021) data. Lancet 14:1–10
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“158,161,164,165 However, activating multiple receptors may lead to more complex side effects, and in some experiments, dual and triple agonists have indeed shown more severe side effects.”
BackgroundAdvance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity
Abasheva, D., Ortíz, A., & Fernández‐Fernández, B. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae296 · Cited by 70
Ullah, M. I., & Tamanna, S. (2025) · Medicines · doi:10.3390/medicines12030019 · Cited by 38
“This multifaceted mechanism targets both caloric intake and energy metabolism and enhances insulin secretion, optimizes glucose homeostasis, and effectively regulates appetite [70].”
Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide
Li, W., Zhou, Q., Cong, Z., Yuan, Q., Li, W., Zhao, F., Xu, H. E., Zhao, L.-H., Yang, D., & Wang, M.-W. (2024) · Cell Discovery · doi:10.1038/s41421-024-00700-0 · Cited by 32
Metadata
- Authors
- Kaur, M., & Misra, S.
- Affiliations
- Kalpana Chawla Government Medical College and Hospital (IN)
- Corresponding author
- Misra, Saurav
- ORCID
- Misra, Saurav
- Venue
- European Journal of Clinical Pharmacology
- Published
- 2024-02-17
- Volume
- 80
- Issue
- 5
- Pages
- 669-676
- ISSN
- 0031-6970 (ISSN-L)
- 1432-1041
- OpenAlex
- W4391899493
- Cited by
- 51
- References
- 35
- Citations by year
- 2026: 7 · 2025: 17 · 2024: 27
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- European Journal of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- retatrutide, obesity, glucagon receptor, glucose-dependent insulinotropic polypeptide receptor, GLP-1 receptor, weight loss, type 2 diabetes, non-alcoholic fatty liver disease, investigational drugs, drug safety and efficacy
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Obesity, Weight Loss, Drugs, Investigational, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. https://app.cochat.ai/papers/10.1007/s00228-024-03646-0
- The paper
- Kaur, M., & Misra, S. (2024). A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-024-03646-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.